Aurora-A activation, correlated with hypoxia-inducible factor-1α promotes radiochemoresistance and predicts poor outcome for nasopharyngeal carcinoma

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1586-1594

  Wan, Xiang Bo ^a,b,c   Fan, Xin Juan ^a   Huang, Pei Yu ^c   Dong, Dong ^d   Zhang, Yan ^c   Chen, Ming Yuan ^c   Xiang, Jin ^c   Xu, Jie ^c   Liu, Li ^c   Zhou, Wei Hua ^a,c   Lv, Yan Chun ^c   Wu, Xiang Yuan ^a   Hong, Ming Huang ^c   Liu, Quentin ^a,b,c  

^a SUN YAT SEN UNIVERSITY   (China)

^b DALIAN MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; CARBOPLATIN; FLOXURIDINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHEMOSENSITIVITY; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RADIOSENSITIVITY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

BLOTTING, WESTERN; CHEMORADIOTHERAPY; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNOHISTOCHEMISTRY; MALE; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROTEIN-SERINE-THREONINE KINASES; RADIATION TOLERANCE; SURVIVAL ANALYSIS; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME;

EID: 84864302944     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02332.x     Document Type: Article

References (47)

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365: 2041-54.
2. Hong B, Lui VW, Hashiguchi M, Hui EP, Chan AT. Targeting tumor hypoxia in nasopharyngeal carcinoma. Head Neck 2011; doi: 10.1002/hed.21877 [Epub ahead of print].
3. Chua DT, Ma J, Sham JS et al. Long-term survival after cisplatin-based induction chemotherapy and radiotherapy for nasopharyngeal carcinoma: a pooled data analysis of two phase III trials. J Clin Oncol 2005; 23: 1118-24.
4. Hong MH, Mai HQ, Min HQ, Ma J, Zhang EP, Cui NJ. A comparison of the Chinese 1992 and fifth-edition International Union Against Cancer staging systems for staging nasopharyngeal carcinoma. Cancer 2000; 89: 242-7.
5. Leung SF, Zee B, Ma BB et al. Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma. J Clin Oncol 2006; 24: 5414-8.
6. Chan AT, Lo YM, Zee B et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002; 94: 1614-9.
7. Lin JC, Chen KY, Wang WY et al. Detection of Epstein-Barr virus DNA in the peripheral-blood cells of patients with nasopharyngeal carcinoma: relationship to distant metastasis and survival. J Clin Oncol 2001; 19: 2607-15.
8. Xu J, Wan XB, Huang XF et al. Serologic antienzyme rate of Epstein-Barr virus DNase-specific neutralizing antibody segregates TNM classification in nasopharyngeal carcinoma. J Clin Oncol 2010; 28: 5202-9.
9. Kalyankrishna S, Grandis JR. Epidermal growth factor receptor biology in head and neck cancer. J Clin Oncol 2006; 24: 2666-72.
10. Rubin Grandis J, Melhem MF, Gooding WE et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998; 90: 824-32.
11. Wan XB, Fan XJ, Chen MY et al. Elevated Beclin 1 expression is correlated with HIF-1alpha in predicting poor prognosis of nasopharyngeal carcinoma. Autophagy 2010; 6: 395-404.
12. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.
13. Rodriguez MO, Rivero TC, del Castillo Bahi R et al. Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck. Cancer Biol Ther 2010; 9: 343-9.
14. Rojo F, Gracias E, Villena N et al. Pharmacodynamic trial of nimotuzumab in unresectable squamous cell carcinoma of the head and neck: a SENDO Foundation study. Clin Cancer Res 2010; 16: 2474-82.
15. Talavera A, Friemann R, Gomez-Puerta S et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res 2009; 69: 5851-9.
16. Yang C, Tang X, Guo X et al. Aurora-B mediated ATM Serine 1403 phosphorylation is required for mitotic ATM activation and the spindle checkpoint. Mol Cell 2011; 44: 597-608.
17. Khan J, Ezan F, Cremet JY et al. Overexpression of active aurora-C kinase results in cell transformation and tumour formation. PLoS ONE 2011; 6: e26512.
18. Meraldi P, Honda R, Nigg EA. Aurora kinases link chromosome segregation and cell division to cancer susceptibility. Curr Opin Genet Dev 2004; 14: 29-36.
19. Liu Q, Ruderman JV. Aurora A, mitotic entry, and spindle bipolarity. Proc Natl Acad Sci U S A 2006; 103: 5811-6.
20. Marumoto T, Zhang D, Saya H. Aurora-A - a guardian of poles. Nat Rev Cancer 2005; 5: 42-50.
21. Tatsuka M, Sato S, Kitajima S et al. Overexpression of Aurora-A potentiates HRAS-mediated oncogenic transformation and is implicated in oral carcinogenesis. Oncogene 2005; 24: 1122-7.
22. Bischoff JR, Anderson L, Zhu Y et al. A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. EMBO J 1998; 17: 3052-65.
23. Zhou H, Kuang J, Zhong L et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet 1998; 20: 189-93.
24. Klein A, Flugel D, Kietzmann T. Transcriptional regulation of serine/threonine kinase-15 (STK15) expression by hypoxia and HIF-1. Mol Biol Cell 2008; 19: 3667-75.
25. Jeng YM, Peng SY, Lin CY, Hsu HC. Overexpression and amplification of Aurora-A in hepatocellular carcinoma. Clin Cancer Res 2004; 10: 2065-71.
26. Kao SY, Chen YP, Tu HF et al. Nuclear STK15 expression is associated with aggressive behaviour of oral carcinoma cells in vivo and in vitro. J Pathol 2010; 222: 99-109.
27. Shang X, Burlingame SM, Okcu MF et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009; 8: 2461-9.
28. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008; 14: 4455-62.
29. Tanaka E, Hashimoto Y, Ito T et al. The suppression of aurora-A/STK15/BTAK expression enhances chemosensitivity to docetaxel in human esophageal squamous cell carcinoma. Clin Cancer Res 2007; 13: 1331-40.
30. Reiter R, Gais P, Jutting U et al. Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma. Clin Cancer Res 2006; 12: 5136-41.
31. Grandis JR. Prognostic biomarkers in head and neck cancer. Clin Cancer Res 2006; 12: 5005-6.
32. Guan Z, Wang XR, Zhu XF et al. Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells. Cancer Res 2007; 67: 10436-44.
33. Wan XB, Long ZJ, Yan M et al. Inhibition of Aurora-A suppresses epithelial-mesenchymal transition and invasion by downregulating MAPK in nasopharyngeal carcinoma cells. Carcinogenesis 2008; 29: 1930-7.
34. Huang PY, Mai HQ, Luo DH et al. Induction-concurrent chemoradiotherapy versus induction chemotherapy and radiotherapy for locoregionally advanced nasopharyngeal carcinoma. Ai Zheng 2009; 28: 1033-42.
35. Zlobec I, Steele R, Terracciano L, Jass JR, Lugli A. Selecting immunohistochemical cut-off scores for novel biomarkers of progression and survival in colorectal cancer. J Clin Pathol 2007; 60: 1112-6.
36. Hui EP, Chan AT, Pezzella F et al. Coexpression of hypoxia-inducible factors 1alpha and 2alpha, carbonic anhydrase IX, and vascular endothelial growth factor in nasopharyngeal carcinoma and relationship to survival. Clin Cancer Res 2002; 8: 2595-604.
37. Wan XB, Fan XJ, Chen MY et al. Inhibition of Aurora-A results in increased cell death in 3-dimensional culture microenvironment, reduced migration and is associated with enhanced radiosensitivity in human nasopharyngeal carcinoma. Cancer Biol Ther 2009; 8: 1500-6.
38. Mancini M, Aluigi M, Leo E et al. Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457. Br J Haematol 2011; 156: 265-8.
39. Huang XF, Luo SK, Xu J et al. Aurora kinase inhibitory VX-680 increases Bax/Bcl-2 ratio and induces apoptosis in Aurora-A-high acute myeloid leukemia. Blood 2008; 111: 2854-65.
40. Harrington EA, Bebbington D, Moore J et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-7.
41. Traynor AM, Hewitt M, Liu G et al. Phase I dose escalation study of MK-0457, a novel Aurora kinase inhibitor, in adult patients with advanced solid tumors. Cancer Chemother Pharmacol 2010; 67: 305-14.
42. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010; 11: 21-8.
43. Ma BB, Kam MK, Leung SF et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Ann Oncol 2012; 23: 1287-92.
44. Wang LH, Xiang J, Yan M et al. The mitotic kinase Aurora-A induces mammary cell migration and breast cancer metastasis by activating the Cofilin-F-actin pathway. Cancer Res 2010; 70: 9118-28.
45. Lee SL, Rouhi P, Dahl Jensen L et al. Hypoxia-induced pathological angiogenesis mediates tumor cell dissemination, invasion, and metastasis in a zebrafish tumor model. Proc Natl Acad Sci U S A 2009; 106: 19485-90.
46. Chan CM, Ma BB, Hui EP et al. Cyclooxygenase-2 expression in advanced nasopharyngeal carcinoma-a prognostic evaluation and correlation with hypoxia inducible factor 1alpha and vascular endothelial growth factor. Oral Oncol 2007; 43: 373-8.
47. Katayama H, Sasai K, Kawai H et al. Phosphorylation by aurora kinase A induces Mdm2-mediated destabilization and inhibition of p53. Nat Genet 2004; 36: 55-62.